PL3848375T3 - Sposoby wytwarzania związków pośrednich dla modulatorów receptorów toll-podobnych - Google Patents

Sposoby wytwarzania związków pośrednich dla modulatorów receptorów toll-podobnych

Info

Publication number
PL3848375T3
PL3848375T3 PL20207453.0T PL20207453T PL3848375T3 PL 3848375 T3 PL3848375 T3 PL 3848375T3 PL 20207453 T PL20207453 T PL 20207453T PL 3848375 T3 PL3848375 T3 PL 3848375T3
Authority
PL
Poland
Prior art keywords
toll
methods
receptor modulators
preparing intermediates
intermediates
Prior art date
Application number
PL20207453.0T
Other languages
English (en)
Inventor
Darin Allen
Brandon Heath BROWN
Jessica Jade Chao
Randall L. Halcomb
Paul Hrvatin
Ryan Mcfadden
Paul Roethle
Erwina Rudio
Hong Yang
Richard Hung Chiu Yu
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3848375T3 publication Critical patent/PL3848375T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
PL20207453.0T 2014-09-16 2015-09-14 Sposoby wytwarzania związków pośrednich dla modulatorów receptorów toll-podobnych PL3848375T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051044P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
PL3848375T3 true PL3848375T3 (pl) 2024-05-06

Family

ID=54291584

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20207453.0T PL3848375T3 (pl) 2014-09-16 2015-09-14 Sposoby wytwarzania związków pośrednich dla modulatorów receptorów toll-podobnych
PL18205728T PL3461828T3 (pl) 2014-09-16 2015-09-14 Sposoby wytwarzania modulatorów receptorów toll-podobnych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18205728T PL3461828T3 (pl) 2014-09-16 2015-09-14 Sposoby wytwarzania modulatorów receptorów toll-podobnych

Country Status (20)

Country Link
US (1) US9573952B2 (pl)
EP (3) EP3194402B1 (pl)
JP (4) JP6373490B2 (pl)
KR (3) KR102457426B1 (pl)
CN (2) CN107074860B (pl)
AR (1) AR101882A1 (pl)
AU (2) AU2015318062B2 (pl)
BR (1) BR112017005100A2 (pl)
CA (1) CA2960384C (pl)
EA (1) EA201790373A1 (pl)
ES (2) ES2706527T3 (pl)
IL (1) IL250849A0 (pl)
MX (1) MX2017003288A (pl)
NZ (1) NZ729526A (pl)
PL (2) PL3848375T3 (pl)
PT (2) PT3461828T (pl)
SG (1) SG11201701472VA (pl)
SI (1) SI3461828T1 (pl)
TW (2) TWI692468B (pl)
WO (1) WO2016044183A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
EP3194401B1 (en) 2014-09-16 2020-10-21 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
CN111065636B (zh) * 2017-09-22 2022-08-23 江苏恒瑞医药股份有限公司 稠合杂芳基衍生物、其制备方法及其在医药上的应用
WO2023212121A2 (en) * 2022-04-26 2023-11-02 Bigelow Laboratory For Ocean Sciences Methods for producing halogenated compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JP2886570B2 (ja) 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
JPH05320143A (ja) * 1992-03-18 1993-12-03 Mochida Pharmaceut Co Ltd 新規ピリミジン誘導体
TW274550B (pl) 1992-09-26 1996-04-21 Hoechst Ag
WO1995018616A2 (en) 1994-01-03 1995-07-13 Acea Pharm Inc 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
PL331602A1 (en) 1996-08-06 1999-08-02 Pfizer Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives
US5693641A (en) 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
CA2334332A1 (en) 1998-06-26 2000-01-06 Robert Joseph Mchugh Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
HUP0202713A3 (en) 1999-09-15 2005-02-28 Warner Lambert Co Pteridinones as kinase inhibitors
US6452325B1 (en) 2000-07-24 2002-09-17 Thermoplastic Processes, Inc. Shatterproofing of fluorescent lamps
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
PT1427730E (pt) 2001-09-04 2006-11-30 Boehringer Ingelheim Pharma Novas di-hidropteridinonas, processo para sua preparação e sua utilização como medicamento
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
RS52386B (en) 2003-02-26 2013-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg. DIHYDROPTERIDINONE, PROCEDURE FOR THEIR PREPARATION AND THEIR APPLICATION AS A MEDICINE
AU2005249212B2 (en) 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006117670A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
EP1915155A1 (en) 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones in the treatment of respiratory diseases
JPWO2007034917A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規なアデニン化合物
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
AU2007223801A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
AU2007227664A1 (en) 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2009541284A (ja) 2006-06-23 2009-11-26 アストラゼネカ・アクチエボラーグ プテリジン誘導体およびカテプシン阻害剤としてのそれらの使用
KR20140104060A (ko) 2006-10-19 2014-08-27 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
WO2008101867A1 (en) 2007-02-19 2008-08-28 Smithkline Beecham Corporation Purine derivatives as immunomodulators
DK2139892T3 (da) 2007-03-22 2011-12-12 Takeda Pharmaceutical Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
WO2008124703A2 (en) 2007-04-05 2008-10-16 Siemens Medical Solutions Usa, Inc. Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
WO2008124575A1 (en) 2007-04-05 2008-10-16 Smithkline Beecham Corporation Renin inhibitors
EP2143724B1 (en) * 2007-04-18 2013-12-11 Kissei Pharmaceutical Co., Ltd. Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
WO2009023269A2 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
WO2009022185A2 (en) 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
WO2009067547A1 (en) 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CN101284810A (zh) 2008-06-02 2008-10-15 秦引林 氰基吡咯烷和氰基噻唑烷衍生物
AU2009333559B2 (en) * 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
NZ598384A (en) * 2009-09-14 2014-04-30 Gilead Sciences Inc Modulators of toll-like receptors
TW201701876A (zh) * 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療c型肝炎病毒(hcv)之方法

Also Published As

Publication number Publication date
AU2015318062A1 (en) 2017-03-16
JP6373490B2 (ja) 2018-08-15
TWI780423B (zh) 2022-10-11
EP3848375A1 (en) 2021-07-14
JP2019214626A (ja) 2019-12-19
AU2015318062B2 (en) 2018-07-05
EP3848375C0 (en) 2023-12-27
PT3194402T (pt) 2019-02-11
CN115043840A (zh) 2022-09-13
JP7063865B2 (ja) 2022-05-09
CN107074860B (zh) 2022-07-15
CA2960384C (en) 2019-07-23
SG11201701472VA (en) 2017-04-27
EP3461828B1 (en) 2020-11-25
NZ729526A (en) 2018-05-25
KR101978809B1 (ko) 2019-05-15
EP3461828A2 (en) 2019-04-03
WO2016044183A1 (en) 2016-03-24
JP2017526729A (ja) 2017-09-14
EP3194402B1 (en) 2018-11-21
JP6596127B2 (ja) 2019-10-23
KR20210118985A (ko) 2021-10-01
TWI692468B (zh) 2020-05-01
KR102457426B1 (ko) 2022-10-24
EA201790373A1 (ru) 2017-08-31
JP2018158953A (ja) 2018-10-11
EP3461828A3 (en) 2019-05-01
PT3461828T (pt) 2021-01-26
ES2845205T3 (es) 2021-07-26
BR112017005100A2 (pt) 2017-12-05
ES2706527T3 (es) 2019-03-29
AU2018236824B2 (en) 2020-04-23
AU2018236824A1 (en) 2018-10-18
SI3461828T1 (sl) 2021-01-29
JP7333843B2 (ja) 2023-08-25
CN107074860A (zh) 2017-08-18
TW201625524A (zh) 2016-07-16
JP2022051834A (ja) 2022-04-01
CA2960384A1 (en) 2016-03-24
KR20190053292A (ko) 2019-05-17
PL3461828T3 (pl) 2021-07-19
AR101882A1 (es) 2017-01-18
EP3194402A1 (en) 2017-07-26
IL250849A0 (en) 2017-04-30
US20160075707A1 (en) 2016-03-17
TW202043195A (zh) 2020-12-01
EP3848375B1 (en) 2023-12-27
KR20170048592A (ko) 2017-05-08
MX2017003288A (es) 2017-06-28
KR102306860B1 (ko) 2021-09-30
US9573952B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
IL250754A0 (en) Solid forms of toll-like receptor modulators
ZA201700880B (en) Polymorphs of selinexor
SG11201700070QA (en) Modulators of toll-like receptors for the treatment of hiv
HUE049398T2 (hu) Hivatkozási jelek mérésének javítása szinkronizáló jelek segítségével
SG11201605786SA (en) Infrastructure for synchronization of mobile device with mobile cloud service
IL249456A0 (en) Methods for preparing analogues of modified nucleotides
EP3212657A4 (en) Methods of preparing substituted nucleoside analogs
ZA201700342B (en) Novel glp-1 receptor modulators
HK1232231A1 (zh) 定點誘變 抗體以降低粘度
EP3224261A4 (en) Opioid receptor modulators
HK1245278A1 (zh) 製備索非布韋晶型6的方法
IL250849A0 (en) Methods for preparing toll-like receptor modulators
EP3230280A4 (en) Process for preparation of luliconazole
ZA201605239B (en) Use of certificates using a positive list
PL3180658T3 (pl) Bezpieczna konfiguracja instalacji automatyki domowej
IL249160A0 (en) Crystal forms of an estrogen receptor modulator
IL252565B (en) New receptor modulators
PT3172232T (pt) Mutagénese dirigida ao local de anticorpos trem-1 para diminuição da viscosidade
EP3193842A4 (en) Methods of preparing extrudates
AU2015905333A0 (en) Modulators of Endosomal G Protein-Coupled Receptors
EP3177737A4 (en) Novel modulators of melanocortin receptors
HK1198459A2 (en) Connecting apparatus for construction
GB201405403D0 (en) Receptor modulation